205452-86-4

Basic information

• Product Name: 2-(1H-tetrazol-5-yl)benzaldehyde
• Synonyms: 2-(1H-tetrazol-5-yl)benzaldehyde
• CAS NO: 205452-86-4
• Molecular Weight: 174.162
• Mol File: 205452-86-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-(1H-tetrazol-5-yl)benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1H-tetrazol-5-yl)benzaldehyde(205452-86-4)
• EPA Substance Registry System: 2-(1H-tetrazol-5-yl)benzaldehyde(205452-86-4)

Safety Data

• Hazardous Substances Data: 205452-86-4(Hazardous Substances Data)

Upstream product

• 7468-67-9 o-formylbenzonitrile 
• 18039-42-4 5-Phenyl-1H-tetrazole 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 1401235-39-9 (Z)-5-(2-(1H-tetrazol-5-yl)benzylidene)-4-thioxothiazolidin-2-one 
• 1198208-17-1 2-(1-benzyl-1H-tetrazol-5-yl)benzaldehyde 

Relevant articles and documents

Tetrazole derivative and preparation thereof, pharmaceutical composition containing tetrazole derivative and application of tetrazole derivative

The invention discloses a tetrazole derivative having a structure represented by a general formula I, wherein R1 is H, a C1-C3 alkyl chain or a halogenated alkyl chain. The invention also discloses acomposition containing the tetrazole derivative and an application of the tetrazole derivative in preparation of medicines for preventing and resisting cerebral apoplexy. Repeated experiments prove that the compound has an obvious inhibition effect on ADP-induced platelet aggregation activity, and has a good protection effect on OGD/R-damaged primary mouse nerve cell models and good rat oral medicine pharmacokinetic properties. Therefore, the compound disclosed by the invention can be used as a neuroprotective agent to be applied to medicines for treating and preventing cerebral apoplexy.

Benzotetrazole derivatives and preparation thereof, pharmaceutical compositions containing benzotetrazole derivatives and application of benzotetrazole derivatives

The invention discloses benzotetrazole derivatives. The benzotetrazole derivatives have a structure represented by a general formula I or a general formula I'. In the general formula I or the generalformula I', R1 is a C3-C5 alkyl chain or a halogenated a

Pyrimidine derivatives and processes for the preparation thereof

4-Amino-1H-pyrazolo[3,4-d]pyrimidine derivatives of formula I wherein the substituents are as defined in claim 1, are described.These compounds inhibit the tyrosine kinase activity of the receptor for epidermal growth factor (EGF) and c-erbB2 kinase and can be used as anti-tumor agents.